NT-2512-00012

NT-2512-00012

i
MR4

MSSB, Healthcare,

RM 200,000 for 18 month term. RM 166,820 funded 18 Days Left

83 % Funded

Is this a Shariah-compliant Investment Note? / Adakah ianya Nota Pelaburan patuh Syariah?

Yes/Ya

Who is the Issuer and what does the business do? / Siapakah Penerbit dan apakah perniagaan yang dijalankan?

The issuer is a leading aesthetic and wellness medical center in the Klang Valley, Malaysia, offering a range of aesthetic, dermatology, regenerative, and wellness treatments that are safe and medically supervised.

The issuer provides specialised services in wellness & regenerative medicine and also aesthetic & weight management

With over 10 years in operation, the issuer is known for high-quality treatments using modern technology. The team includes experienced doctors, certified nurses, and trained therapists dedicated to excellent patient care.

The issuer serves local residents, corporate clients, and international patients, with all services provided on-site at the clinic.
__________________________________________________________________________________
Penerbit adalah pusat perubatan estetika dan kesejahteraan terkemuka di Lembah Klang, Malaysia, yang menawarkan rawatan estetika, dermatologi, regeneratif, dan kesejahteraan yang selamat serta diawasi secara perubatan.

Penerbit menyediakan perkhidmatan khusus dalam bahagian kesihatan & perubatan regeneratif serta estetika & pengurusan berat badan.

Beroperasi lebih 10 tahun, penerbit dikenali kerana menyediakan rawatan berkualiti tinggi menggunakan teknologi moden. Pasukannya terdiri daripada doktor, jururawat bertauliah, dan ahli terapi terlatih yang komited memberikan penjagaan pesakit yang cemerlang.

Penerbit melayani penduduk tempatan, pelanggan korporat, dan pesakit antarabangsa, dengan semua perkhidmatan disediakan di klinik.

Who is the owner / key person(s) in the business? / Siapakah pemilik / individu penting dalam perniagaan?

The issuer is led by an experienced owner with over 25 years in the healthcare and service-management sector, including expertise in clinic operations, business development, and implementing efficient systems for sustainable growth. The leadership actively oversees medical operations, streamlines workflow processes, and guides teams across various functions.

The issuer is supported by a dedicated team of 12 staff covering operations, customer service, finance, and administration. Each team member brings valuable expertise to ensure services are delivered professionally, consistently, and aligned with the clinic’s objectives.
__________________________________________________________________________________
Penerbit ini diketuai oleh seorang pemilik berpengalaman dengan lebih 25 tahun dalam sektor penjagaan kesihatan dan pengurusan perkhidmatan, termasuk kepakaran dalam operasi klinik, pembangunan perniagaan, dan pelaksanaan sistem yang efisien untuk menyokong pertumbuhan mampan. Pihak pengurusan turut terlibat secara aktif dalam memantau operasi perubatan, memperkemas proses kerja, dan membimbing pasukan merentasi pelbagai fungsi.

Penerbit ini disokong oleh pasukan berdedikasi seramai 12 kakitangan yang merangkumi operasi, khidmat pelanggan, kewangan, dan pentadbiran. Setiap ahli pasukan membawa kepakaran berharga untuk memastikan perkhidmatan diberikan secara profesional, konsisten, dan selaras dengan objektif klinik.

What are their future plans? / Apakah rancangan masa depan mereka?

The issuer aims to grow sales and expand services. By January 2026, it will offer wellness, stem-cell, and hormone treatments to meet rising demand for advanced regenerative solutions.

It is also targeting medical tourism, attracting international patients with high-quality, medically supervised aesthetic and wellness services.

This strategy helps the issuer serve both local and international demand, supporting sustainable growth and better returns for investors.
__________________________________________________________________________________
Penerbit memberi tumpuan kepada kenaikan jualan dan pengembangan perkhidmatan. Menjelang Januari 2026, ia akan menawarkan rawatan kesihatan, stem-cell, dan hormon bagi memenuhi permintaan untuk rawatan regeneratif dan kesejahteraan.

Penerbit juga menyasarkan pasaran pelancongan perubatan, menarik pesakit antarabangsa dengan perkhidmatan estetika dan kesejahteraan yang berkualiti tinggi dan diawasi secara perubatan.

Strategi ini membolehkan penerbit memenuhi permintaan tempatan dan antarabangsa, menyokong pertumbuhan mampan dan pulangan lebih baik untuk pelabur.

What has been their annual sales turnover? / Berapakah jumlah perolehan jualan tahunan mereka?

YTD September 2025 total Revenue: RM 1,424,081
FYE February 2025 total Revenue: RM 2,068,858
FYE February 2024 total Revenue: RM 830,055 __________________________________________________________________________________
YTD September 2025 jumlah hasil: RM 1,424,081
FYE Februari 2025 jumlah hasil: RM 2,068,858
FYE Februari 2024 jumlah hasil: RM 830,055

Number of years in business? / Berapa lamakah perniagaan ini telah beroperasi?

The business started in 2015 and is currently in its 10th year in the industry.
__________________________________________________________________________________
Perniagaan ini bermula pada 2015 dan kini berada dalam tahun ke-10 dalam industri.

How would the Issuer utilise the funds raised on the platform? / Bagaimanakah Penerbit akan menggunakan dana yang diperoleh di platform?

Renovation & Interior Refurbishment – Upgrade the facility to enhance patient experience and accommodate growth.

Medical Machinery & Equipment – Purchase and install equipment to expand aesthetic and wellness services.

Working Capital & Medication – Support day-to-day operations and purchase necessary medication.
__________________________________________________________________________________
Pengubahsuaian & Refurbishment Dalaman – Menambahbaik fasiliti untuk meningkatkan keselesaan pesakit dan menyokong pertumbuhan.

Peralatan Perubatan & Mesin – Membeli dan memasang peralatan bagi mengembangkan perkhidmatan estetika dan kesejahteraan.

Modal Kerja & Ubat-Ubatan – Menyokong operasi harian serta pembelian ubat-ubatan yang diperlukan.

The rationale behind the Issuer's Credit Risk Score - microLEAP's Comments

Please download the Factsheet in this Investment Note for more information.
This is the first Investment Note hosted by the Issuer.

The Issuer has sufficient revenue to manage its payment to microLEAP and both the Issuer and Guarantors have shown a good payment track record with other lenders. We have Standing Instructions (SI) in place to ensure prompt payment of the profit and principal into our Trust account.

As rated by Experian, the Issuer's Company i-score is rated as 7 (Good) with a Probability of Default (PD) of >2.5%-5%. While the first Guarantor is rated as 5 (Fair) with a PD of >10%-20% and the second Guarantor is rated as 8 (Good) with a PD of >1.5%-2.5%.

This Investment Note has an MR4(Medium Risk 4) rating and so it has a high credit quality and medium risk of default.
__________________________________________________________________________________
Sila muat turun Lembaran Fakta yang dilampirkan dalam Nota Pelaburan ini untuk maklumat lanjut.
Ini merupakan Nota Pelaburan yang pertama oleh Penerbit.

Penerbit mempunyai hasil yang mencukupi untuk mengurus pembayarannya kepada microLEAP dan kedua-dua Penerbit dan Penjamin telah menunjukkan rekod prestasi pembayaran yang baik dengan pemberi pinjaman yang lain. Kami mempunyai Arahan Tetap (SI) untuk memastikan pembayaran segera keuntungan dan prinsipal ke dalam akaun Amanah kami.

Seperti yang dinilai oleh Experian, i-skor Syarikat Pengeluar dinilai sebagai 7 (Bagus) dengan Kebarangkalian Lalai (PD) >2.5%-5%. Manakala, penjamin Pertama dinilai sebagai 5 (Sederhana) dengan PD >10%-20% dan penjamin kedua dinilai sebagai 8 (Bagus) dengan PD >1.5%-2.5%.

Nota Pelaburan ini mempunyai penarafan MR4 (Risiko Sederhana 4) dan oleh itu ia mempunyai kualiti kredit tinggi dan risiko kegagalan pembayaran yang sederhana.

Invest Now
Rate of Returns
14.8% p.a
Total Gross Return on Investment
-


Terms & Conditions Apply

Credit Ratings
MR4
Medium Risk 4

This Investment Note pays a medium-low Interest Rate and has a medium-low Risk of Default.
It has a medium-strong Credit Quality due to average to good cashflow and average to good Debt Service Ratio.
.

LR1
Low Risk 1

This Investment Note pays the lowest Interest Rate and has the lowest Risk of Default.
It has the strongest Credit Quality due to very high cashflow and very low Debt Service Ratio.

LR2
Low Risk 2

This Investment Note pays a lower Interest Rate and has a lower Risk of Default.
It has a stronger Credit Quality due to high cashflow and low Debt Service Ratio.

LR3
Low Risk 3

This Investment Note pays a low Interest Rate and has a low Risk of Default.
It has a strong Credit Quality due to good cashflow and good Debt Service Ratio.

MR4
Medium Risk 4

This Investment Note pays a medium-low Interest Rate and has a medium-low Risk of Default.
It has a medium-strong Credit Quality due to average to good cashflow and average to good Debt Service Ratio.
.

MR5
Medium Risk 5

This Investment Note pays a medium Interest Rate and has a medium Risk of Default.
It has a medium Credit Quality due to average cashflow and average Debt Service Ratio.

MR6
Medium Risk 6

This Investment Note pays a medium-high Interest Rate and has a medium-high Risk of Default.
It has a medium-weak Credit Quality due to below average cashflow and above average Debt Service Ratio.

MR7
Medium Risk 7

This Investment Note pays an upper-medium Interest Rate and has an upper-medium Risk of Default.
It has a lower-medium Credit Quality due to average to low cashflow and average to high Debt Service Ratio.

HR8
High Risk 8

This Investment Note pays a high Interest Rate and has a high Risk of Default.
It has a weak Credit Quality due to low cashflow and high Debt Service Ratio.

HR9
High Risk 9

This Investment Note pays a higher Interest Rate and has a higher Risk of Default.
It has a weaker Credit Quality due to lower cashflow and higher Debt Service Ratio.

HR10
High Risk 10

This Investment Note pays the highest Interest Rate and has the highest Risk of Default.
It has the weakest Credit Quality due to very low cashflow and very unhealthy Debt Service Ratio.

View Funding List